Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.

Reuters warns that Novo Nordisk's growth rate is slowing. Singapore bank DBS says the stock is a sell. But at 18 times earnings and with a growth rate of 16% or better, Novo Nordisk actually looks ...

Shares of Novo Nordisk (NYSE: NVO) are up on Tuesday. The company's stock gained 3.9% as of 2:40 p.m. ET today and was up as much as 4.5% earlier in the day. The move up comes as the S&P 500 and ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Novo Nordisk announced it is partnering with telehealth platforms to offer its blockbuster drug Wegovy. The move will help it capture a large number of consumers who had flocked to digital health ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard ...

Credit: Novo Nordisk. Self-paying patients will now be able to access NovoCare Pharmacy directly through the telehealth platform. The Company is working with Hims & Hers Health, Inc, LifeMD ...

A lot went wrong for Novo Nordisk A/S in the last six months, and a lot went right for competitor Eli Lilly. Novo Nordisk's competitive positioning in the obesity market has worsened, but I ...

BANGKOK, April 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's local subsidiary ...

Novo Nordisk works with Hims & Hers, Ro, LifeMD to expand Wegovy access Hims & Hers, LifeMD shares jump more than 25% and 36% respectively Danish drugmaker says move is "very clear message" Wegovy ...